Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor

Open access
Dikmen, Z. Gunnur, Gellert, Ginelle C., Jackson, Shalmica, Gryaznov, Sergei, Tressler, Robert, Dogan, Pakize, Wright, Woodring E., Shay, Jerry W. · 2005 · Cancer Research

Abstract

Differential regulation of telomerase activity in normal and tumor cells provides a rationale for the design of new classes of telomerase inhibitors. The telomerase enzyme complex presents multiple potential sites for the development of inhibitors. GRN163L, a telomerase enzyme antagonist, is a lipid-modified 13-mer oligonucleotide N3′ → P5′-thio-phosphoramidate, complementary to the template region of telomerase RNA (hTR). We evaluated both the in vitro and in vivo effects of GRN163L using A549-luciferase (A549-Luc) human lung cancer cells expressing a luciferase reporter. GRN163L (1 μmol/L) effectively inhibits telomerase activity of A549-Luc cells, resulting in progressive telomere shortening. GRN163L treatment also reduces colony formation in soft agar assays. Surprisingly, after only 1 week of treatment with GRN163L, A549-Luc cells were unable to form robust colonies in the clonal efficiency assay, whereas the mismatch control compound had no effect. Finally, we show that in vivo treatment with GRN163L is effective in preventing lung metastases in xenograft animal models. These in vitro and in vivo data support the development of GRN163L as a therapeutic for the treatment of cancer.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-1215

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 272

Metadata

Authors
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W.
Affiliations
  • 1University of Hacettepe, Faculty of Medicine, Department of Biochemistry, Ankara, Turkey;
  • The University of Texas Southwestern Medical Center (US)
  • Geron (United States) (US)
  • Harold C. Simmons Comprehensive Cancer Center (US)
Venue
Cancer Research
Published
2005-09-01
Volume
65
Issue
17
Pages
7866-7873
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2125343208
Cited by
271
References
47
Citations by year
2026: 4 · 2025: 9 · 2024: 10 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 13 · 2019: 8 · 2018: 14 · 2017: 7 · 2016: 12 · 2015: 10 · 2014: 14 · 2013: 9 · 2012: 7
FWCI
13.20
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
Funders
National Cancer Institute (P50CA75907, CA86354, P20CA086354)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
GRN163L, telomerase inhibitors, lung cancer, telomerase RNA template, phosphoramidate prodrug, telomere shortening, A549 cells, colony formation, lung metastasis, xenograft models, cancer therapy
MeSH terms
Animals, Enzyme Inhibitors, Humans, Liposomes, Luciferases, Lung Neoplasms, Mice, Nude, Oligonucleotides, Sulfur Radioisotopes, Tissue Distribution, Neoplastic Stem Cells, Telomerase, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-1215
The paper
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005). In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-1215

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.